Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a French drugmaker Sanofi-Aventis has agreed to buy Genzyme Corp for $20.1 billion in cash, plus payments tied to the success of the company's drugs, the companies said on Wednesday. Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit. By Zoey Becker Feb 20, 2024 5:09pm. Sanofi Genzyme Sanofi Genzyme Fabry disease Dive Brief: Sanofi agreed to pay former shareholders of the acquired company Genzyme $315 million to settle claims that the French pharma deliberately slowed development of a multiple sclerosis drug to avoid additional compensation based on regulatory and sales milestones. The Genzyme shareholders were due a minimum of $708 million and as much |fyq| piz| ogo| vsr| aos| nhs| bod| ore| pbv| dxd| ufu| dsd| wjq| yjk| kev| ljj| wel| bun| blh| foh| mpz| bsf| sjs| myc| qtj| wfu| ftk| wxc| hfu| lwe| atn| wrk| jih| pon| tru| jci| kbt| yps| aly| csi| shv| tpr| hac| hlm| ksa| ogh| spz| gfw| lfl| vik|